Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Int J Oncol. 2013 Apr;42(4):1305-16. doi: 10.3892/ijo.2013.1819. Epub 2013 Feb 8.
Chemokine (C-C motif) ligand 21 (CCL21) and SPARC-like protein 1 (SPARCL1/MAST9/hevin/SC-1) are associated with various biological behavior in the development of cancers. Although the expression of CCL21 and SPARCL1 is downregulated in many solid tumors, their roles in ovarian cancer and their associations with drug resistance have rarely been studied. We performed a comprehensive bioinformatic analysis consisting of motif analysis, literature co-occurrence, gene/protein-gene/protein interaction network, protein-small molecule interaction network, and microRNAs enrichments which revealed that CCL21 and SPARCL1 directly or indirectly interact with a number of genes, proteins, small molecules and pathways associated with drug resistance in ovarian and other cancers. These results suggested that CCL21 and SPARCL1 may contribute to drug resistance in ovarian cancer. This study provided important information for further investigation of drug resistance-related functions of CCL21 and SPARCL1 in ovarian cancer.
趋化因子(C-C 基序)配体 21(CCL21)和 SPARC 样蛋白 1(SPARCL1/MAST9/hevin/SC-1)与癌症发展中的各种生物学行为有关。虽然 CCL21 和 SPARCL1 在许多实体瘤中表达下调,但它们在卵巢癌中的作用及其与耐药性的关系很少被研究。我们进行了一项综合的生物信息学分析,包括基序分析、文献共现、基因/蛋白质-基因/蛋白质相互作用网络、蛋白质-小分子相互作用网络和 microRNAs 富集,结果表明 CCL21 和 SPARCL1 直接或间接与许多与卵巢癌和其他癌症耐药性相关的基因、蛋白质、小分子和途径相互作用。这些结果表明 CCL21 和 SPARCL1 可能有助于卵巢癌的耐药性。本研究为进一步研究 CCL21 和 SPARCL1 在卵巢癌中与耐药性相关的功能提供了重要信息。